vs
ANI PHARMACEUTICALS INC（ANIP）与Artisan Partners Asset Management Inc.（APAM）财务数据对比。点击上方公司名可切换其他公司
Artisan Partners Asset Management Inc.的季度营收约是ANI PHARMACEUTICALS INC的1.4倍（$335.5M vs $247.1M），Artisan Partners Asset Management Inc.净利率更高（35.2% vs 11.1%，领先24.1%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 12.9%），Artisan Partners Asset Management Inc.自由现金流更多（$171.6M vs $29.1M），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 12.7%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
阿蒂森伙伴资产管理公司（Artisan Partners）是总部位于美国威斯康星州密尔沃基的资产管理机构，除美国本土外，还在都柏林、香港、伦敦、新加坡、悉尼设有办公室，为全球客户提供专业的资产管理服务。
ANIP vs APAM — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $335.5M |
| 净利润 | $27.5M | $118.1M |
| 毛利率 | — | — |
| 营业利润率 | 14.1% | 39.2% |
| 净利率 | 11.1% | 35.2% |
| 营收同比 | 29.6% | 12.9% |
| 净利润同比 | 367.5% | 34.9% |
| 每股收益（稀释后） | $1.14 | $1.36 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $247.1M | $335.5M | ||
| Q3 25 | $227.8M | $301.3M | ||
| Q2 25 | $211.4M | $282.7M | ||
| Q1 25 | $197.1M | $277.1M | ||
| Q4 24 | $190.6M | $297.1M | ||
| Q3 24 | $148.3M | $279.6M | ||
| Q2 24 | $138.0M | $270.8M | ||
| Q1 24 | $137.4M | $264.4M |
| Q4 25 | $27.5M | $118.1M | ||
| Q3 25 | $26.6M | $66.8M | ||
| Q2 25 | $8.5M | $67.6M | ||
| Q1 25 | $15.7M | $61.1M | ||
| Q4 24 | $-10.3M | $87.5M | ||
| Q3 24 | $-24.2M | $73.0M | ||
| Q2 24 | $-2.3M | $57.6M | ||
| Q1 24 | $18.2M | $59.5M |
| Q4 25 | 14.1% | 39.2% | ||
| Q3 25 | 15.9% | 33.8% | ||
| Q2 25 | 6.6% | 28.2% | ||
| Q1 25 | 13.3% | 31.2% | ||
| Q4 24 | -2.3% | 36.7% | ||
| Q3 24 | -13.8% | 33.3% | ||
| Q2 24 | 3.7% | 32.0% | ||
| Q1 24 | 14.8% | 29.4% |
| Q4 25 | 11.1% | 35.2% | ||
| Q3 25 | 11.7% | 22.2% | ||
| Q2 25 | 4.0% | 23.9% | ||
| Q1 25 | 8.0% | 22.1% | ||
| Q4 24 | -5.4% | 29.5% | ||
| Q3 24 | -16.3% | 26.1% | ||
| Q2 24 | -1.7% | 21.3% | ||
| Q1 24 | 13.2% | 22.5% |
| Q4 25 | $1.14 | $1.36 | ||
| Q3 25 | $1.13 | $0.93 | ||
| Q2 25 | $0.36 | $0.94 | ||
| Q1 25 | $0.69 | $0.82 | ||
| Q4 24 | $-0.45 | $0.99 | ||
| Q3 24 | $-1.27 | $1.03 | ||
| Q2 24 | $-0.14 | $0.80 | ||
| Q1 24 | $0.82 | $0.84 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | — |
| 总债务越低越好 | — | $190.0M |
| 股东权益账面价值 | $540.7M | $438.8M |
| 总资产 | $1.4B | $1.6B |
| 负债/权益比越低杠杆越低 | — | 0.43× |
8季度趋势，按日历期对齐
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | — | ||
| Q2 25 | $217.8M | — | ||
| Q1 25 | $149.8M | — | ||
| Q4 24 | $144.9M | — | ||
| Q3 24 | $145.0M | — | ||
| Q2 24 | $240.1M | — | ||
| Q1 24 | $228.6M | — |
| Q4 25 | — | $190.0M | ||
| Q3 25 | — | $190.0M | ||
| Q2 25 | — | $200.0M | ||
| Q1 25 | — | $200.0M | ||
| Q4 24 | — | $200.0M | ||
| Q3 24 | — | $200.0M | ||
| Q2 24 | — | $200.0M | ||
| Q1 24 | — | $200.0M |
| Q4 25 | $540.7M | $438.8M | ||
| Q3 25 | $505.8M | $402.1M | ||
| Q2 25 | $436.8M | $381.8M | ||
| Q1 25 | $418.6M | $356.5M | ||
| Q4 24 | $403.7M | $388.9M | ||
| Q3 24 | $405.9M | $372.1M | ||
| Q2 24 | $455.8M | $341.2M | ||
| Q1 24 | $452.0M | $320.3M |
| Q4 25 | $1.4B | $1.6B | ||
| Q3 25 | $1.4B | $1.6B | ||
| Q2 25 | $1.3B | $1.4B | ||
| Q1 25 | $1.3B | $1.4B | ||
| Q4 24 | $1.3B | $1.6B | ||
| Q3 24 | $1.3B | $1.6B | ||
| Q2 24 | $920.8M | $1.5B | ||
| Q1 24 | $914.5M | $1.5B |
| Q4 25 | — | 0.43× | ||
| Q3 25 | — | 0.47× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | 0.56× | ||
| Q4 24 | — | 0.51× | ||
| Q3 24 | — | 0.54× | ||
| Q2 24 | — | 0.59× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $172.0M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $171.6M |
| 自由现金流率自由现金流/营收 | 11.8% | 51.2% |
| 资本支出强度资本支出/营收 | 0.5% | 0.1% |
| 现金转化率经营现金流/净利润 | 1.10× | 1.46× |
| 过去12个月自由现金流最近4个季度 | $171.4M | $420.6M |
8季度趋势，按日历期对齐
| Q4 25 | $30.4M | $172.0M | ||
| Q3 25 | $44.1M | $40.4M | ||
| Q2 25 | $75.8M | $50.9M | ||
| Q1 25 | $35.0M | $157.9M | ||
| Q4 24 | $15.9M | $372.8M | ||
| Q3 24 | $12.5M | $112.8M | ||
| Q2 24 | $17.4M | $75.9M | ||
| Q1 24 | $18.3M | $147.0M |
| Q4 25 | $29.1M | $171.6M | ||
| Q3 25 | $38.0M | $40.4M | ||
| Q2 25 | $71.8M | $50.9M | ||
| Q1 25 | $32.5M | $157.7M | ||
| Q4 24 | $13.5M | $371.3M | ||
| Q3 24 | $7.7M | $112.4M | ||
| Q2 24 | $13.0M | $75.2M | ||
| Q1 24 | $13.7M | $146.9M |
| Q4 25 | 11.8% | 51.2% | ||
| Q3 25 | 16.7% | 13.4% | ||
| Q2 25 | 34.0% | 18.0% | ||
| Q1 25 | 16.5% | 56.9% | ||
| Q4 24 | 7.1% | 125.0% | ||
| Q3 24 | 5.2% | 40.2% | ||
| Q2 24 | 9.4% | 27.8% | ||
| Q1 24 | 10.0% | 55.6% |
| Q4 25 | 0.5% | 0.1% | ||
| Q3 25 | 2.7% | 0.0% | ||
| Q2 25 | 1.9% | 0.0% | ||
| Q1 25 | 1.3% | 0.1% | ||
| Q4 24 | 1.3% | 0.5% | ||
| Q3 24 | 3.2% | 0.1% | ||
| Q2 24 | 3.2% | 0.2% | ||
| Q1 24 | 3.3% | 0.0% |
| Q4 25 | 1.10× | 1.46× | ||
| Q3 25 | 1.66× | 0.60× | ||
| Q2 25 | 8.87× | 0.75× | ||
| Q1 25 | 2.23× | 2.58× | ||
| Q4 24 | — | 4.26× | ||
| Q3 24 | — | 1.54× | ||
| Q2 24 | — | 1.32× | ||
| Q1 24 | 1.00× | 2.47× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
APAM
暂无分部数据
